Literature DB >> 20188257

Antigen engineering can play a critical role in the protective immunity elicited by Yersinia pestis DNA vaccines.

Shixia Wang1, Innocent Mboudjeka, Jon D Goguen, Shan Lu.   

Abstract

The use of a DNA immunization approach to deliver protective antigens against Yersinia pestis (Y. pestis) has been successful in previously reported studies. In the current study, the gene designs for V and F1, two well-studied virulent factors serving as main targets for vaccine development, were altered to explore additional options in hopes of improving the protective immunity of DNA vaccines expressing these two antigens. Compared to the wild type V gene DNA vaccines, the use of codon optimized V gene sequences was effective in improving the antigen expression, titers of anti-V antibody responses, and survival against a mucosal lethal challenge. For the F1 DNA vaccine, removal of the N-terminal hydrophobic region was able to improve protective immunity. However, adding a mammalian signal peptide sequence to F1 actually led to reduced protection despite it inducing slightly higher anti-F1 antibody responses. The F1 gene can be fused with a gene coding for YscF, a newly confirmed partial protective antigen for Y. pestis, to produce DNA vaccines that express fused F1 and YscF antigens. One design, in particular, that had YscF fused to the downstream sequence of F1, produced better protection than separate F1 or YscF DNA vaccines, suggesting a potential synergistic effect between these two antigens. Findings from the above studies indicated that there are multiple approaches to optimize the protective immunity for plague DNA vaccines. Most importantly, proper antigen engineering to produce optimal antigen gene inserts in DNA vaccines can clearly play a major role in the future designs of a wide range of DNA vaccines. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20188257      PMCID: PMC2830910          DOI: 10.1016/j.vaccine.2009.10.059

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  42 in total

1.  Influence of codon usage on the immunogenicity of a DNA vaccine against tetanus.

Authors:  R Stratford; G Douce; L Zhang-Barber; N Fairweather; J Eskola; G Dougan
Journal:  Vaccine       Date:  2000-11-22       Impact factor: 3.641

2.  Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines.

Authors:  Shixia Wang; Jessica Taaffe; Christopher Parker; Alicia Solórzano; Hong Cao; Adolfo García-Sastre; Shan Lu
Journal:  J Virol       Date:  2006-09-20       Impact factor: 5.103

Review 3.  Plague immunization. I. Past and present trends.

Authors:  K F Meyer; D C Cavanaugh; P J Bartelloni; J D Marshall
Journal:  J Infect Dis       Date:  1974-05       Impact factor: 5.226

4.  Pathology of experimental pneumonic plague produced by fraction 1-positive and fraction 1-negative Yersinia pestis in African green monkeys (Cercopithecus aethiops).

Authors:  K J Davis; D L Fritz; M L Pitt; S L Welkos; P L Worsham; A M Friedlander
Journal:  Arch Pathol Lab Med       Date:  1996-02       Impact factor: 5.534

5.  Protection studies following bronchopulmonary and intramuscular immunisation with yersinia pestis F1 and V subunit vaccines coencapsulated in biodegradable microspheres: a comparison of efficacy.

Authors:  J E Eyles; E D Williamson; I D Spiers; H O Alpar
Journal:  Vaccine       Date:  2000-08-01       Impact factor: 3.641

Review 6.  Immunogenicity of DNA vaccines in humans: it takes two to tango.

Authors:  Shan Lu
Journal:  Hum Vaccin       Date:  2008-11-28

7.  Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague.

Authors:  S E Leary; E D Williamson; K F Griffin; P Russell; S M Eley; R W Titball
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

8.  Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection.

Authors:  Ying-Kit Cheung; Samuel Chak-Sum Cheng; Fion Wan-Yee Sin; Yong Xie
Journal:  Vaccine       Date:  2004-12-16       Impact factor: 3.641

9.  Effect of homologous and heterologous prime-boost on the immune response to recombinant plague antigens.

Authors:  Audrey Glynn; Lucy C Freytag; John D Clements
Journal:  Vaccine       Date:  2005-03-14       Impact factor: 3.641

10.  An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.

Authors:  Alexandre Harari; Pierre-Alexandre Bart; Wolfgang Stöhr; Gonzalo Tapia; Miguel Garcia; Emmanuelle Medjitna-Rais; Séverine Burnet; Cristina Cellerai; Otto Erlwein; Tristan Barber; Christiane Moog; Peter Liljestrom; Ralf Wagner; Hans Wolf; Jean-Pierre Kraehenbuhl; Mariano Esteban; Jonathan Heeney; Marie-Joelle Frachette; James Tartaglia; Sheena McCormack; Abdel Babiker; Jonathan Weber; Giuseppe Pantaleo
Journal:  J Exp Med       Date:  2008-01-14       Impact factor: 14.307

View more
  2 in total

1.  Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge.

Authors:  Shixia Wang; Jon D Goguen; Fusheng Li; Shan Lu
Journal:  Vaccine       Date:  2011-01-01       Impact factor: 3.641

2.  Pilot Study on the Use of DNA Priming Immunization to Enhance Y. pestis LcrV-Specific B Cell Responses Elicited by a Recombinant LcrV Protein Vaccine.

Authors:  Wei Li; Shixia Wang; Shan Lu
Journal:  Vaccines (Basel)       Date:  2013-12-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.